This month several new drugs were introduced on the Canadian market:
- Xenpozyme (olipudase alfa) is a medication used for the treatment of non-central nervous system (CNS) manifestations of acid sphingomyelinase deficiency type A/B or type B.
- Beyfortus (nirsevimab) is a human recombinant monoclonal antibody with activity against respiratory syncytial virus (RSV).
- Elrexfio (elranatamab) is a medication used for the treatment of multiple myeloma.